HCV infection and kidney transplantation outcomes

HCV infection and kidney transplantation outcomes concerns the tension between increased post-transplant risk and the persistent survival benefit of receiving a kidney. Hepatitis C virus infection is the leading cause of chronic liver disease in kidney transplant recipients and is associated with inferior long-term patient and graft survival, yet transplantation remains the preferred renal replacement therapy for most infected patients who do not have advanced liver injury.

Definition and Clinical Setting

HCV infection enters the transplant pathway before surgery, beginning with screening, assessment of active viremia, and staging of liver injury. HCV is more prevalent among patients with chronic kidney disease than in the general population, and its consequences begin while candidates remain on dialysis or the kidney waiting list. In a Spanish collaborative review of transplant recipients transplanted in 1990, 1994, and 1998, anti-HCV prevalence fell from 29.5% to 19% and then to 10%, reflecting the effects of improved prevention, screening, and treatment. The decline reduced the number of infected candidates and recipients, but it did not remove the clinical problem: infected candidates may still have advanced liver disease, and immunosuppression can accelerate hepatic injury after transplantation.

The pre-transplant evaluation therefore distinguishes antibody positivity from active infection. Candidates are screened with anti-HCV antibody testing and, depending on local prevalence, confirmation or initial assessment with nucleic acid testing. A positive NAT result requires specialist hepatology evaluation and may place the candidate on hold while treatment and staging are considered. Liver biopsy remains the most reliable method for determining the extent of fibrosis in an HCV-infected kidney transplant candidate. Studies found advanced liver injury, including stage 3 or 4 disease and cirrhosis, in approximately 10–25% of candidates who underwent biopsy. Established or decompensated cirrhosis changes the transplant plan: such patients should be referred for consideration of simultaneous liver–kidney transplantation rather than proceeding automatically to kidney-alone transplantation.

Waiting List and Treatment Decisions

The waiting list is not a neutral interval for an HCV-infected patient. In some areas of the United States, deceased-donor waiting times approach five to seven years, long enough for liver disease to progress. Candidates with active viremia require continuing surveillance, while those who have achieved a sustained virological response should undergo NAT at least annually to confirm that the response persists. Relapse warrants hold status and referral for retreatment. Patients who remain viremic need periodic reassessment of liver disease, including repeat biopsy according to fibrosis stage: approximately every five years for Metavir stage 1 or 2 fibrosis and about every three years for stage 3 fibrosis. Progression to early or established cirrhosis should lead to removal from the kidney-only list and referral to a liver transplant team.

The timing of antiviral therapy is consequently central to outcome. Eradication before transplantation is generally favored because post-transplant interferon therapy is associated with an increased risk of renal allograft rejection. Pre-transplant sustained virological response may also reduce the risk of post-transplant diabetes and immune-complex glomerular disease, although its effect on later liver injury and overall graft or patient survival was not definitively established. Treatment itself can be difficult: interferon-associated toxicity includes flu-like symptoms, anemia, neutropenia, depression, and anxiety; adverse effects lead to dose reduction in roughly 35–42% of patients and treatment discontinuation in about 30%.

Not every patient can complete or receive antiviral therapy. Treatment may be prolonged, expensive, poorly tolerated, unavailable, refused, or unsuccessful, and patients may be excluded from the waiting list while undergoing therapy. For these patients, remaining on dialysis may be more dangerous than proceeding to transplantation despite persistent HCV RNA. This is one context in which a kidney from an HCV-positive donor may be considered for an HCV-positive recipient: the principal potential benefit is a shorter waiting time. Organ scarcity sharpens the decision. At the end of 2009, the European Union had about 63,000 people waiting for an organ but only 28,000 transplant procedures during that year; in the United States, nearly 111,000 people were listed in May 2011 while annual procedures numbered about 28,000. HCV-positive kidneys were reported to be 2.60 times more likely to be discarded than HCV-negative kidneys, making donor serology both a clinical risk marker and a resource-allocation issue.

Patient Survival After Transplantation

HCV-positive recipients have worse long-term survival than uninfected recipients, particularly in studies extending beyond ten years after transplantation. Shorter studies often found little or no difference, and the evidence is limited by retrospective designs, reliance on ELISA classification rather than more accurate nucleic acid testing, and the absence of pre-transplant liver biopsies in many cohorts. Those limitations matter because they can blur the distinction between the consequences of HCV itself and the consequences of liver damage that was already present before transplantation.

The comparison that most directly informs clinical choice is not infected versus uninfected recipients, but transplantation versus continued dialysis among infected patients. Several observational studies found lower mortality after transplantation. In one report, the relative risk of death for anti-HCV-positive recipients was 0.31 during the period from seven to forty-eight months after transplantation compared with patients who remained on the waiting list. In a cohort of 175 listed candidates with documented HCV infection, the hazard ratio for death was initially 2.51 during the first six months after transplantation, but fell to 0.32 during months seven through eighty-four. The early hazard and later reversal express the central paradox of the relationship: transplantation may carry substantial immediate risk, yet it offers a marked subsequent survival advantage over remaining on dialysis when advanced liver injury does not preclude kidney transplantation.

The excess mortality among infected recipients reflects several interacting causes. Cardiovascular disease, progressive liver disease, and serious infection all occur more often in the HCV-positive cohort. HCV infection is also associated with post-transplant lymphoproliferative disease and other extrahepatic neoplasias. In an Italian analysis of more than 1,000 liver, heart, and kidney recipients, post-transplant lymphoproliferative disease occurred in 3.6% of anti-HCV-positive patients compared with 1.2% of anti-HCV-negative patients. Registry data also suggested an association with multiple myeloma, although the relationship requires further confirmation. The resulting conclusion is not that transplantation should be withheld from every infected candidate, but that immunosuppression, infection, liver disease, and malignancy must be followed as connected risks.

Graft Survival and Renal Complications

HCV infection is an independent risk factor for graft loss. In a comparison of 488 anti-HCV-positive recipients with 2,877 seronegative recipients, the adjusted relative risk of graft loss was 1.53. Data from the Australian and New Zealand Dialysis and Transplant Registry found an adjusted hazard ratio of 1.71 for graft failure at five years among anti-HCV-positive recipients. Graft loss in that cohort was more often attributed to glomerulonephritis, with an adjusted hazard ratio of 2.71, and chronic allograft nephropathy, with an adjusted hazard ratio of 1.87.

Several renal lesions connect HCV infection to this poorer graft trajectory. Proteinuria may arise from chronic allograft nephropathy, interstitial fibrosis and tubular atrophy, or HCV-associated glomerulonephritis. HCV-positive status was identified as an independent risk factor for post-transplant proteinuria. In biopsy series of patients with proteinuria, chronic allograft nephropathy was the most frequent lesion, and nearly half of anti-HCV-positive patients had transplant glomerulopathy. The association was not entirely consistent across studies, but one analysis found anti-HCV antibodies in 33% of patients with transplant glomerulopathy compared with 1.9% of those without it. The proposed mechanism is endothelial injury caused directly or indirectly by HCV, possibly through cytokine release, including interferon-related pathways, eventually expressed as transplant glomerulopathy.

HCV-related glomerulonephritis and new-onset diabetes after transplantation add further routes to graft dysfunction. The broader clinical pattern includes proteinuria, renal insufficiency, chronic rejection, and transplant glomerulopathy rather than a single isolated lesion. These complications help explain why graft survival is lower even when early post-transplant outcomes appear similar between infected and uninfected recipients.

Long-Term Management and Overall Significance

Because HCV-positive recipients remain vulnerable to several distinct forms of deterioration, post-transplant care requires more than routine graft surveillance. Immunosuppression should be managed carefully, and outpatient follow-up should seek early evidence of proteinuria, declining graft function, infection, new-onset diabetes after transplantation, malignancy, and worsening liver disease. The risk of infection-related death has been repeatedly observed, although the relative effects of particular immunosuppressive agents remain uncertain. The possibility of post-transplant lymphoproliferative disease and other hematologic malignancies also supports close clinical surveillance.

The overall relationship is therefore adverse but not uniformly prohibitive. Compared with anti-HCV-negative recipients, infected recipients experience higher mortality, more liver and cardiovascular disease, more serious infections, more proteinuria and renal lesions, and greater risk of graft loss. Compared with remaining on dialysis, however, transplantation still provides the better long-term renal replacement strategy for patients without advanced liver injury. The decisive clinical task is to transform infection status into an individualized plan: identify active viremia, measure fibrosis accurately, treat before transplantation when feasible, monitor the waiting list for progression, consider simultaneous liver–kidney transplantation when cirrhosis demands it, and preserve the survival advantage of kidney transplantation through disciplined post-transplant follow-up.